Advancements in Treating Chemotherapy Side Effects – A New Standard of Care for Preventing Hand-Foot Syndrome – Igryl S. Cordero, MD

Patients undergoing treatment for breast or gastrointestinal cancers with the chemotherapy drug capecitabine (Xeloda®) may develop hand-foot syndrome (HFS). A common treatment side-effect, HFS can lead to redness, swelling, skin peeling, and sometimes painful blisters on the palms and soles. Although the syndrome is not life-threatening, it can cause significant discomfort and negatively impact a […]

Investigational Inhibitor of Active RAS Shows Clinical Promise – Alexander I. Spira, MD, PhD, FACP

Investigational Inhibitor of Active RAS Shows Clinical Promise –  The therapy uses a different mechanism than approved KRAS G12C inhibitors and targets multiple RAS mutations beyond KRAS G12C  

Landmark Non-Small Cell Lung Cancer Study – Clinically Meaningful Improvement and Progression Free Survival, Alexander I. Spira, MD, PhD, FACP 

Virginia Cancer Specialists Research Institute – Landmark “Non-Small Cell Lung Cancer Study” – Alexander I. Spira, MD, PhD, FACP  Planned interim overall survival analysis showed a trend favoring the combination of RYBREVANT® and lazertinib compared to osimertinib* First pivotal study to show a clinically meaningful benefit in a chemotherapy-free regimen versus osimertinib  – See the […]